Deviations in the Pharmaceutical Industry

by | Mar 16, 2022 | Compliance, Consulting Group, QMS, Quality, Quality Systems, Regulatory, Standardization, Standards


A deviation is any unwanted event that differs from the approved processes, procedures, instructions, specifications, or established standards. Deviations can occur during the manufacturing, packing, sampling, and testing of drug products.

There are three types of deviations, critical, major, and minor. A critical deviation affects the quality of a critical process parameter, equipment, or instrument or has an immediate patient safety risk or life-threatening situation. A major deviation impacts a product’s quality, safety, or efficacy but may not have a direct impact on patients. A minor deviation affects a utility, equipment, material, component, or documentation but does not affect product quality or the physical state of the product or its labeling.

GMP requires deviations to be documented. This assists with continuous improvement. FDA § 211.192 requires a thorough investigation[1]. The Quality Management System should ensure that deviations from established procedures are identified and recorded.

The responsible department along with quality assurance should evaluate the scope of the deviation, potential quality impact, trends relating to similar products, materials, equipment, and testing processes, a review of similar causes, regulatory commitment impact, other batches that could potentially be affected, and market actions. Investigation of critical deviations should be completed within 15 working days, major deviations within 20 working days, and minor deviations within 30 working days.

Deviations occur in the workplace but having a system in place to ensure they are documented correctly is necessary. If your company needs assistance with its deviation management, EMMA International can assist. Contact us by phone at 248-987-4497 or by email at info@emmainternational.com.


[1] FDA (Jan 2022) CFR-Code of Federal Regulations Title 21. Retrieved on March 14, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=211.192


Bano Ahmed

Bano Ahmed

Bano is a Quality Engineer at EMMA International. She has experience in quality control, pharmaceutical and medical device manufacturing, and implementing corrective and preventative actions within the pharmaceutical and medical device industries. Bano has earned a Bachelor of Science in Biology from Pennsylvania State University and a MPH in Population Health Sciences from the University of Michigan.

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This